Sunho Biologics,Inc. (HK:2898) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sunho Biologics, Inc. has reported its unaudited interim financial results for the first half of 2024, highlighting a reduction in loss for the period to RMB 36,077 thousand compared to RMB 61,489 thousand in the same period last year. The Group’s financial health appears to be on the rise with a significant increase in cash and cash equivalents from RMB 125.1 million to RMB 493.9 million. Despite increased R&D and listing expenses, the overall financial loss has decreased, signaling a potential turnaround for the company.
For further insights into HK:2898 stock, check out TipRanks’ Stock Analysis page.